The assessment of the cardiovascular risk in rheumatoid arthritis patients on anti TNF therapy

被引:0
|
作者
Anghel, Daniela [1 ,2 ]
Petrache, Oana G. [1 ]
Groseanu, Maria L. [4 ]
Sirbu, Carmen A. [1 ,4 ]
Opris-Belinski, Daniela [3 ,4 ]
Radu, Florentine Ionita [1 ,4 ]
机构
[1] Cent Mil Emergency Univ Hosp, Bucharest, Romania
[2] Titu Maiorescu Univ, Fac Med, Bucharest, Romania
[3] Sfanta Maria Hosp, Bucharest, Romania
[4] Carol Davila Univ Med & Pharm, Bucharest, Romania
关键词
cardiovascular risk; intima media thickness; hiperhomocysteinemia; rheumatoid arthritis; anti-tumor necrosis factor alpha therapy; INTIMA-MEDIA THICKNESS; HEART-FAILURE; NITRIC-OXIDE; METAANALYSIS; DISEASE; INFLAMMATION; ASSOCIATION; SMOKING;
D O I
10.55453/rjmm.2022.125.3.17
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Auto-immune rheumatic diseases are characterised by high levels of inflammation that accelerate the development of atherosclerosis, increasing the cardiovascular risk. Direct evaluation of arteries such as of intima media thickness measurement is a simple test that asesses the cerebral and cardiovascular risk. In the initial stages, an increase of the intimal media thickness can be observed. Later on, atherosclerosis (plaques), stenosis and occlusion of the arteries can be identified. Indirect evaluation of the cardiovascular risk can be performed using serological markers - fibrinogen, C reactive protein, estimated sedimentation rate, total cholesterol, low density lipoproteins and high density lipoproteins, homocysteine levels etc. The presence of certain lifestyle factors that increase the risk, such as smoking, sedentarism and associated pathologies such as obesity, diabetes, hypertension were assesed in patients with rheumatoid arthritis. The aim of the study is to prove the relationship between anti-tumor necrosis factor alpha therapy effect on the cardiovascular risk in rheumatoid arthritis patients.
引用
收藏
页码:469 / 474
页数:6
相关论文
共 50 条
  • [1] EVALUATION OF CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANTI-TNF-ALPHA THERAPY
    Anghel, D.
    Panturu, L.
    Jurcut, V. C.
    Muresan, M. M.
    Dilirici, E. L.
    Negru, M. M.
    Bursuc, R. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 275 - 276
  • [2] FRACTURE RISK ASSESSMENT (FRAX) IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THERAPY WITH ANTI-TNFα
    Anghel, D.
    Otlocan, L.
    Negru, M. M.
    Busuioc, E.
    Bursuc, R.
    Smedescu, V.
    Manolache, A.
    Jurcut, C.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S400 - S400
  • [3] Influence of anti-TNF therapy on the cardiovascular risk factors in patients with active rheumatoid arthritis
    Popa, C
    Netea, MG
    Radstake, T
    Van der Meer, JWM
    Stalenhoef, A
    Van Riel, PL
    Barrera, P
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 274 - 274
  • [4] Assessment of Cardiovascular Risk in Patients with Rheumatoid Arthritis
    Matteson, Eric L.
    Mankad, Rekha
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (11) : 1947 - 1949
  • [5] USE OF ANTI-TNF THERAPY IS ASSOCIATED WITH REDUCED CARDIOVASCULAR EVENT RISK IN RHEUMATOID ARTHRITIS
    Nurmohamed, M. T.
    Bao, Y.
    Signorovitch, J.
    Mulani, P. M.
    Furst, D. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 52 - 52
  • [6] Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs
    Avouac, J.
    Allanore, Y.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (07) : 1121 - 1128
  • [7] ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS
    Feldmann, M.
    Brennan, F.
    Williams, R. O.
    Monaco, C.
    Maini, R.
    INFLAMMATION RESEARCH, 2011, 60 : 31 - 31
  • [8] Surgery in rheumatoid arthritis patients under anti-TNF-α therapy: what is the risk?
    Daniel Wendling
    Clinical Rheumatology, 2007, 26 : 1396 - 1397
  • [9] Effect of anti-TNF therapy and corticosteroids on the risk of stroke in patients with rheumatoid arthritis
    Michaud, K.
    Naclareishvili, Z.
    Wolfe, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 182 - 183
  • [10] Surgery in rheumatoid arthritis patients under anti-TNF-α therapy:: what is the risk?
    Wendling, Daniel
    CLINICAL RHEUMATOLOGY, 2007, 26 (08) : 1396 - 1397